Avelumab binds PD-L1 on target cells and, via its IgG1 Fc, engages NK cells (CD16) to trigger antibody-dependent cellular cytotoxicity (ADCC), directly killing PD-L1-positive cells; PD-1/PD-L1 blockade also enhances T-cell killing (indirect).